Japanese, Chinese Regulators Step Up Communications To Increase Effectiveness, Speed Up Approval - DIA China Conference
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Communication with regulators is essential for clinical development success and increasingly drug companies are engaging with multiple regulators simultaneously along parallel tracks; regulators are responding in some surprising ways that show they are willing to change, leaders from China and Japan told scientists and executives at the China Drug Information Association meeting in Beijing May 18
You may also be interested in...
Approval Agency Reforms In Asia Leave Mark On Drug Pricing – DIA Asia New Drug Development Conference
Drug development doesn’t happen in a bubble. Speakers at DIA’s Asia New Drug Development Conference in Tokyo urged attendees to consider the impact of unique government pricing mechanisms in the region when bringing a new product to market.
China's Device Classification System And Country Of Origin Requirements Weigh On Foreign Companies
BEIJING - Foreign medical device manufacturers frustrated with China's medical device classification system and country of origin requirements are starting to take an "if you can't beat them, joint them" approach and are shifting more manufacturing to China, according to panelists at a recent regulatory conference in Beijing
China's Device Classification System And Country Of Origin Requirements Weigh On Foreign Companies
BEIJING - Foreign medical device manufacturers frustrated with China's medical device classification system and country of origin requirements are starting to take an "if you can't beat them, joint them" approach and are shifting more manufacturing to China, according to panelists at a recent regulatory conference in Beijing